ABSTRACT Juniperus phoenicea ssp. Turbinata L. ( J. phoenicea ssp. Turbinata) has long been used in traditional medicine to treat a variety of ailments. This study aimed to investigate the pharmacological potential and to characterize the phytochemical composition of the hydroethanolic leaf (JPEF) and fruit (JPEG) extracts. Liquid Chromatography Tandem Mass Spectrometry (LC–MS/MS) analysis revealed that both JPEF and JPEG contained high levels of phenolic compounds, with ferulic acid identified as the dominant constituent. The biological evaluation began with acute toxicity tests in rodents, which indicated that JPEF and JPEG extracts were well tolerated at the doses administered, with no significant adverse effects observed. The extracts exhibited strong anti‐inflammatory activity (94.23% for JPEF; 83.24% for JPEG), comparable to that of diclofenac (97.02%), as well as a notable analgesic effect (75% and 70.62%), compared to tramadol (87.01%). Significant antioxidant activity was observed (DPPH IC 50 : 70.2 and 90.76 μg/mL), accompanied by antimicrobial activity (bacterial inhibition zones: 11.44–20.36 mm; fungal: 13.59–20.38 mm). Molecular docking revealed a stable interaction between the compounds and several enzymatic targets. These results confirm the potential of J. phoenicea ssp. turbinata as a promising source of therapeutic agents.
Diabetic neuropathy (DN) is a multifactorial complication of diabetes mellitus driven by chronic hyperglycemia, insulin resistance, and disturbed metabolic homeostasis, leading to progressive injury of both the peripheral and central nervous systems. This study investigated whether L-serine supplementation could attenuate DN through dose-dependent metabolic and neuroprotective mechanisms in a high-fat diet (HFD) plus streptozotocin (STZ)-induced diabetic rat model. Male Wistar rats (n = 8 per group) were allocated to five groups: normal control (NC), diabetic control (DC), pioglitazone (PIO; 1.5 mg/kg/day), low-dose L-serine (S1; 200 mg/kg/day), and high-dose L-serine (S2; 400 mg/kg/day). After 60 days of oral gavage, behavioural testing, glucose and insulin profiling, HOMA-IR calculation, brain histopathology, nerve growth factor (NGF) immunohistochemistry, and LC–MS/MS-based proteomic analysis of cerebral tissue were performed. Diabetic rats exhibited marked hyperglycaemia (355.33 ± 4.72 mg/dL), hyperinsulinaemia, severe insulin resistance (HOMA-IR 16.8 ± 3.2; a 14-fold increase), impaired thermal nociception, motor dysfunction, and pronounced neuronal degeneration. L-serine supplementation significantly improved metabolic status: S1 reduced HOMA-IR by 77.4% and S2 by 87.5% relative to diabetic controls (p < 0.001). High-dose L-serine produced greater improvements in thermal sensitivity, motor coordination (rotarod latency 26.67 ± 1.52 s vs. 16.1 ± 0.85 s in DC; p < 0.05), and NGF expression (8.6-fold increase vs. DC). Histopathology confirmed attenuation of neuronal injury and gliosis in both treatment groups. Exploratory, group-level proteomic profiling identified dose-specific molecular signatures: S1 was predominantly associated with carbohydrate, lipid, and biosynthetic pathways, whereas S2 was associated with synaptic, neurotransmission-related, and proteostasis pathways. Within the constraints of an exploratory design—group-level pooled proteomics, analysis of cerebral rather than peripheral-nerve tissue, and only two doses—these findings indicate that L-serine attenuates the metabolic and behavioural features of experimental diabetic neuropathy and generates the testable hypothesis of dose-dependent neuro-metabolic remodelling. The proteomic signatures are hypothesis-generating and require orthogonal validation before any mechanistic or translational inference can be drawn.
BACKGROUND: Vitamin D deficiency is linked to cardiovascular and respiratory instability, particularly during hypoxic stress, such as in obstructive sleep apnea (OSA). However, the mechanisms connecting vitamin D status to hemodynamic and cardiorespiratory responses in hypoxia remain unclear. OBJECTIVE: This study aimed to assess the impact of vitamin D deficiency on hemodynamic (mean arterial pressure and heart rate) and cardiorespiratory (respiratory rate and peripheral oxygen saturation) stability in an OSA experimental model, along with the effects of dose-dependent vitamin D supplementation. METHODS: Fifty-six adult male Sprague Dawley rats were divided into seven groups: control, vitamin D-deficient, vitamin D-deficient with severe intermittent hypoxia (IH) and supplementation subgroups exposed to varying levels of IH. Vitamin D deficiency was induced through a diet lacking vitamin D for three weeks, followed by oral supplementation at two doses (25 µg/kg/day and 37.5 µg/kg/day) for two weeks. Intermittent hypoxia was simulated for 14 days, and serum 25-hydroxyvitamin D (25OHD) levels were measured using Elisa. Hemodynamic and cardiorespiratory parameters were recorded, and heart, aorta tissue were analyzed. RESULTS: Vitamin D-deficient groups exhibited significantly lower serum 25OHD levels and showed increased mean arterial pressure, heart and respiratory rates, and reduced oxygen saturation under hypoxia. High-dose supplementation improved 25OHD levels and improved physiological measures, particularly in moderate hypoxia subgroups (p = 0.001). CONCLUSION: Vitamin D deficiency combined with intermittent hypoxia increased mean arterial pressure, heart rate, and respiratory rate, reduced oxygen saturation, and worsened cardiovascular histology. Vitamin D supplementation improved these changes, especially at higher dose, and protected cardiovascular structures.
vitamin D deficiencyvitamin D supplementationobstructive sleep apneaintermittent hypoxia
Background Early prophylactic low-dose hydrocortisone has been proposed to reduce inflammation and to compensate for relative adrenal insufficiency in extremely preterm infants. Its overall balance of benefit and risk remains uncertain. Objective To evaluate whether hydrocortisone initiated within the first 24–48 h after birth reduces bronchopulmonary dysplasia (BPD) and mortality in infants born before 30 weeks' gestation. Methods This systematic review and meta-analysis followed PRISMA 2020 guidance and was registered in PROSPERO. PubMed, Cochrane CENTRAL, Scopus, and Web of Science were searched from inception to May 2026. Eligible studies enrolled infants born before 30 weeks' gestation who received early prophylactic systemic hydrocortisone at a low dose. Low dose was defined as a starting dose of no more than 2.0 mg/kg/day, begun within 24–48 h of birth. The comparator was placebo or no hydrocortisone. Randomized and quasi-randomized trials, their follow-up reports, and comparative observational studies were eligible. Random-effects meta-analyses were performed using risk ratios (RRs) or mean differences with 95% confidence intervals (CIs). Results Fourteen studies with 3,416 infants were included. Early hydrocortisone did not significantly improve survival without BPD at 36 weeks' postmenstrual age (RR: 1.07, 95% CI: 0.97–1.19, p = 0.18). It also did not significantly reduce BPD at 36 weeks (RR: 0.94, 95% CI: 0.85–1.04, p = 0.25) or mortality before discharge (RR: 1.07, 95% CI: 0.77–1.49, p = 0.69). The duration of respiratory support and the need for oxygen at discharge were similar between groups. Subgroup analyses suggested a possible benefit in infants exposed to chorioamnionitis and in those born before 26 weeks, but these findings were exploratory. Hydrocortisone increased the risk of late-onset sepsis (RR: 1.19, 95% CI: 1.05–1.35, p = 0.01). Gastrointestinal perforation, necrotizing enterocolitis, major neonatal morbidities, and the available neurodevelopmental outcomes did not differ significantly between groups. Conclusion Current evidence does not support the routine use of early prophylactic hydrocortisone in all extremely preterm infants. Adequately powered trials and individual patient data analyses are needed to identify the subgroups most likely to benefit and to clarify long-term safety. Systematic Review Registration https://www.crd.york.ac.uk/prospero/view/CRD420261402317 , PROSPERO CRD420261402317.
Erythema annulare centrifugum (EAC) is a rare reactive dermatosis that can be difficult to manage in persistent cases.A 54-year-old woman presented with pruritic, annular, and polycyclic plaques that subsequently extended to the neck, trunk, upper back, hands, lower legs, and feet.A skin biopsy supported the diagnosis of superficial EAC on clinicopathologic correlation.After limited improvement with topical therapies and oral prednisolone, she received four weekly doses of empiric oral fluconazole 150 mg without adverse effects.The eruption improved, and approximately five months after treatment discontinuation, she remained clear apart from residual post-inflammatory hyperpigmentation.The temporal association suggests a possible treatment response; however, the absence of pretreatment mycologic testing and the possibility of spontaneous remission limit causal interpretation.
Tavapadon is an oral, once-daily, non-catechol partial agonist selective for the D1 and D5 dopamine receptors and represents a mechanistically distinct option currently under clinical investigation for Parkinson disease (PD). This narrative review critically evaluates the biological rationale for D1/D5 receptor targeting, the pharmacological and preclinical development of tavapadon, and the accumulating phase 1–3 clinical evidence for its use as monotherapy in early PD and as adjunctive therapy in patients with motor fluctuations, while highlighting remaining evidence gaps and methodological limitations. A non-systematic literature search of PubMed/MEDLINE, Embase, ClinicalTrials.gov , and Scopus (through May 2026) was performed to identify representative and pivotal randomized controlled trials, pharmacokinetic/pharmacodynamic studies, and mechanistic preclinical investigations relevant to tavapadon and D1/D5 receptor agonism; this narrative approach was not intended to be exhaustive or fully reproducible in the manner of a systematic review. Mechanistically, selective stimulation of the direct striatal pathway together with submaximal intrinsic efficacy at the D1 receptor has been proposed, as a mechanistic hypothesis rather than a demonstrated clinical mechanism, to preserve antiparkinsonian benefit while limiting the receptor-signaling intensity implicated in levodopa-induced dyskinesia. In the phase 2 PARKWAY-II study and the now fully published phase 3 TEMPO-1 and TEMPO-2 trials, fixed- and flexible-dose tavapadon produced clinically meaningful improvements in MDS-UPDRS motor scores compared with placebo in early PD, and in the phase 3 TEMPO-3 trial, adjunctive tavapadon significantly increased daily good ON time and reduced OFF time in levodopa-treated patients with motor fluctuations; efficacy in all trials has been demonstrated only against placebo, with no head-to-head data against levodopa or other dopamine agonists. Adverse events were more frequent with tavapadon than placebo (approximately 72–76% versus 55% across TEMPO-2 and TEMPO-3), with nausea, headache, and dizziness the most common; no excess signal of impulse-control disorders relative to placebo was detected over the available 26–27-week controlled treatment period, and no clinically significant QTc prolongation was observed. The 58-week open-label TEMPO-4 extension, now reported in a peer-reviewed AAN abstract publication in Neurology alongside earlier interim conference data, suggests sustained benefit and a stable long-term levodopa requirement, but lacks a randomized control and cannot yet establish long-term safety superiority over existing agents. Tavapadon is a mechanistically novel candidate with preliminary evidence of efficacy; its ultimate clinical utility will depend on head-to-head trials and long-term safety data.
Post-acne erythema (PAE) is a persistent acne sequela without an established standard treatment. This systematic review evaluated the comparative efficacy and safety of interventions tested in randomized trials. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through August 1, 2026. Randomized parallel-group and split-face trials reporting erythema outcomes were eligible. Risk of bias was assessed with the Cochrane Risk of Bias 2 (RoB 2) tool. Heterogeneity precluded meta-analysis, and available findings were synthesized narratively. Nine trials involving 301 participants contributed 11 pairwise comparisons. Against untreated or blank controls, favorable effects were reported for picosecond alexandrite laser, narrow-spectrum vascular intense pulsed light (IPL), and non-cross-linked hyaluronic acid mesotherapy. A 577-nm semiconductor laser showed interim instrumental benefit, but blinded assessors found no final between-side difference. In active-treatment and add-on comparisons, narrow-spectrum IPL was favored over broad-spectrum IPL, neodymium-doped yttrium aluminum garnet (Nd) laser added to low-dose isotretinoin was favored over isotretinoin alone, and 577-nm pro-yellow laser was favored over topical brimonidine. Botulinum toxin type A was favored over broadband light at the earliest assessment only. Fractional laser and pulsed dye laser did not differ significantly, while delicate pulsed light and Q-switched 1064-nm Nd laser showed no sustained difference at the final assessment. Adverse events were mild and transient, although pigmentation and blistering occurred with one broad-spectrum IPL protocol. Five trials had some concerns, and four had high overall risk of bias. Trials suggested potential benefits, but small samples, heterogeneity, short follow-up, and reporting limitations precluded identification of a preferred treatment. Larger, prospectively registered trials using blinded assessment and standardized outcomes are needed.
Frontiers in Pharmacology · مجلد 17 · 1847011-1847011
Background Endothelial dysfunction driven by intermittent hypoxia (IH)-induced oxidative stress, nitric oxide depletion, and adhesion molecule upregulation underlies obstructive sleep apnea (OSA)-related cardiovascular complications. Vitamin D deficiency, which frequently coexists with OSA, may further amplify this endothelial injury through impaired endothelial nitric oxide synthase (eNOS) regulation and heightened renin-angiotensin-aldosterone system (RAAS) activity; however, the dose-dependent therapeutic potential of vitamin D3 on combined endothelial and renal outcomes in an IH model remains uncharacterized. Methods Fifty-six adult male Sprague-Dawley rats were allocated to seven groups: control, vitamin D-deficient (VDD), VDD with severe IH (SIH-VDD), and four supplementation subgroups receiving high-dose (37.5 μg/kg/day) or low-dose (25 μg/kg/day) cholecalciferol under severe or moderate IH for 14 days. Serum E-selectin, ICAM-1, ET-1, NO, and PCSK9 were quantified by ELISA. Renal histopathology was assessed on H&E sections by a blinded pathologist. Data were analyzed by one-way MANOVA, univariate ANOVA, and LSD post hoc tests (p < 0.05). Results The SIH-VDD group showed the most severe endothelial activation: peak E-selectin (4.92 ± 0.90 ng/mL), ICAM-1 (201.50 ± 21.55 ng/mL), ET-1 (5.31 ± 0.81 pg/mL), and PCSK9 (213.50 ± 14.71 ng/mL), with the lowest NO (14.88 ± 2.16 μmol/L; all p < 0.001 vs. control). High-dose supplementation produced substantial recovery across all markers; PCSK9 normalized to near-control (162.50 ng/mL) under severe IH. Low-dose supplementation yielded incomplete normalization. Renal histopathology revealed mild interstitial lymphocytic infiltration in IH-exposed groups, with proximal tubular vacuolisation exclusively in the SIH-VDD group and entirely absent in all supplemented groups. Glomerular architecture remained preserved throughout. Conclusion Vitamin D deficiency combined with IH upregulates endothelial dysfunction markers and induces renal tubular injury in an experimental OSA model. High-dose vitamin D 3 attenuates these changes dose- and severity-dependently, supporting its role as a pharmacological adjunct for OSA-associated endothelial and renal complications.
Abstract This study evaluated the preventive effects of quercetin (QR) and N-acetylcysteine (NAC), alone or combined, in a rat model of acute acetaminophen (APAP)-induced hepatotoxicity. Twenty-five male rats were allocated to five groups (n = 5): control, APAP, NAC + APAP, QR + APAP, and NAC + QR + APAP. NAC (150 mg/kg) and/or QR (50 mg/kg) were administered orally for 7 days before a single oral APAP dose (2 g/kg). Serum liver-function indices, lipid profile, circulating TNF-α and IL-6, hepatic oxidative-status indices, hepatic COX-2, TGF-β1, Nrf2, and HO-1 mRNA abundance, histopathology, and IL-1β immunohistochemistry were assessed. APAP increased ALT, AST, triglycerides, total cholesterol, TNF-α, IL-6, and hepatic MDA, while decreasing total protein, albumin, HDL-C, GSH, CAT, SOD, and GPx. It also increased COX-2 and TGF-β1 transcripts and decreased Nrf2 and HO-1 transcripts. Pretreatment with NAC or QR partially attenuated these changes, whereas their combination generally produced values closer to control. The combined regimen also reduced histological injury and IL-1β immunoreactivity relative to APAP. These findings support a preventive association between combined NAC/QR exposure and improved redox and inflammatory indices. Because protein abundance, Nrf2 nuclear translocation, treatment after injury, and treatment-only controls were not evaluated, the data do not establish pathway activation, pharmacological synergy, or therapeutic efficacy after established overdose.
Background Irinotecan is a potent chemotherapeutic agent used as a neoadjuvant in colorectal cancer liver metastasis and significantly enhances five-year survival rates. Recently, irinotecan-associated hepatotoxicity was a significant concern. Given the limited study in this area, we aimed to identify risk factors associated with irinotecan-induced hepatotoxicity. Methods This is a retrospective cohort study at King Saud University Medical City in Riyadh. The study encompassed all adult cancer patients who received irinotecan treatment between Jun 2017 and December 2023. The clinical records of patients were reviewed to assess factors associated with hepatotoxicity. Time-to-event analyses were performed using time-varying exposure. Results The study includes 229 adult cancer patients who received irinotecan-based treatment. Median age was 58 years, and colorectal cancer was the most diagnosed type of cancer (68.6%). Over a median follow-up of 103 days, the incidence of hepatotoxicity was 19.2% (n=44). In the adjusted analysis, higher baseline AST was associated with an increased hazard of hepatotoxicity (HR = 1.01; 95% CI: 1.01–1.02; p = 0.001). Cumulative irinotecan dose showed an inverse association with hepatotoxicity, with lower hazards observed in the medium cumulative dose group (HR = 0.36, 95% CI: 0.14–0.91, p = 0.031) and high cumulative dose group (HR = 0.06, 95% CI: 0.01–0.48, p = 0.008) compared with the low cumulative dose group. Conclusion In summary, an inverse association was observed between cumulative irinotecan dose and hepatotoxicity. A higher baseline AST was also associated with hepatotoxicity, warranting careful assessment of pretreatment liver enzymes and closer monitoring during the early treatment period. Further studies are needed to validate these findings and investigate additional predictors of irinotecan-related hepatotoxicity.
Journal of King Saud University - Science · مجلد 38 · 19032025-19032025
Glycyrrhiza glabra ( G. glabra) root is traditionally known for its wide-ranging pharmacological properties, including antimicrobial, anti-inflammatory, hepatoprotective, and immunomodulatory effects. This study aims to explore the anxiolytic potential of G. glabra root decoction. Using LC-MS, seven major phytocompounds such as N-acetylalanine, primuliten, 8-hydroxy-13,14,15,16-tetranor-12-labdanoic acid, gardnerine, abrine canrenoic acid, and aspterric acid were identified from the G. glabra decoction. These compounds were further evaluated through ADME profiling and network pharmacology to assess their drug-likeness and pharmacokinetic properties using the SWISS ADME platform. Among the identified compounds, the bioactive compound canrenoic acid was found to be investigated for the direct modulation of ion channels in the brain contributing to central nervous system (CNS) pharmacology, and for the regulation of CNS stress responses, which can modulate anxiety-related behaviours. Canrenoic acid (PubChem CID: 656615) demonstrated promising interactions with the anxiety-related protein target PDB ID:7E2Y. Molecular dynamics (MD) simulations were conducted over a 100-nanosecond trajectory to analyze the stability of the Canrenoic acid–7E2Y complex. The simulation results revealed minimal conformational fluctuations, with the ligand maintaining a stable binding pose through hydrophobic interactions and hydrogen bonding. root mean square deviation (RMSD), root mean square fluctuation (RMSF), secondary structure evolution, and protein-ligand interaction analyses confirmed the robustness of the complex. In addition, in vivo testing using the elevated plus maze (EPM) was performed in rats to evaluate the anxiolytic effects of four different extracts at two dose levels (100 mg/kg and 200 mg/kg), compared to a standard treatment group (diazepam 2 mg/kg). The G. glabra decoction exhibited significant anxiolytic activity. Rats treated with 200 mg/kg of G. glabra showed a marked increase in both the number of entries into the open arms (3.33 ± 0.21) and the time spent in the open arms (43.83 ± 0.79 seconds), closely mirroring the effects observed with the standard drug diazepam. These findings suggest that canrenoic acid is a promising candidate for further preclinical and clinical evaluation in the treatment of anxiety disorders.
This study reports the isolation, structural elucidation, and biological evaluation of a novel naphthofuran derivative (compound 1), methyl 9-methoxy-4-methylnaphtho[1,2-c]furan-3-carboxylate, along with known compounds; chrysophanol (2) and 2-acetyl-1,8-dimethoxy-3-methylnaphthalene (3) from the aerial parts of Asphodelus microcarpus. The structure was established by 1D/2D NMR and HR-ESI-MS. Compound 1 exhibited potent bactericidal activity against MRSA ATCC 3345 (MIC = 3.13 μg/mL, MBC = 12.5 μg/mL, MBC/MIC = 4) and significant dose-independent antibiofilm activity (maximum inhibition 64.7 ± 0.35% at MIC). Computational studies including ligand-based similarity searching, molecular docking, hydration site analysis, and 500 ns molecular dynamics simulations identified dihydrofolate reductase (DHFR) as a potential target, with compound 1 showing favorable binding (ΔG_bind = −55.13 kcal/mol) driven by π–π stacking with Phe92—a selectivity-determining residue absent in human DHFR (Val115). Comparative docking predicted ~20-fold selectivity for bacterial DHFR. In silico ADMET profiling revealed full drug-likeness compliance with no PAINS or toxicity alerts. Compound 1 represents the first naphthofuran from A. microcarpus with a computationally defined mechanism, positioning it as a promising anti-MRSA lead.
Niclosamide, an FDA-approved anti-helminthic drug, has attracted attention for its potential to target multiple cancer-related pathways. This study evaluated the chemopreventive effect of niclosamide in a DMBA/TPA-induced mouse model of skin carcinogenesis and explored its mechanisms using integrated biological and network-based approaches. Mice were treated with niclosamide at 15, 30, and 45 mg/kg and compared with healthy, disease, and standard therapy controls. Tissue and serum analyses were conducted to measure markers of inflammation (TNF-α, IL-6, IL-1β), oxidative stress (MDA, SOD, GSH), apoptosis (caspase-3, Bax/Bcl-2), and angiogenesis (VEGF). Niclosamide reduced tumor volume in a dose-dependent manner, suppressed inflammatory cytokines, restored antioxidant levels, activated apoptotic signaling, and downregulated VEGF expression. A protein-protein interaction network was constructed using eleven experimentally relevant genes to identify key regulatory modules. Network topology and enrichment analysis revealed two functional clusters associated with inflammation, apoptosis, and redox homeostasis. Hub genes such as TNF, IL6, CASP3, and GPX1 highlighted potential interactions among pathways affected by niclosamide. Thus, these findings suggest that niclosamide may exert anticancer effects by modulating interconnected pathways related to inflammation, oxidative stress, apoptosis, and angiogenesis, supporting its potential for further investigation as a repurposed therapeutic candidate for skin cancer.
Abstract The present study examined the modulatory effects of Ocimum gratissimum leaf flavonoid-rich extracts on the Nrf-2 and HO-1 pathways in the livers of streptozotocin-induced diabetic rats. The animals were divided into five groups ( n = 8). These included a normal control, a diabetic control, diabetic rats administered low (LDOGFL) or high (HDOGFL) doses of Ocimum gratissimum leaf flavonoid-rich extracts at 150 and 300 mg/kg, respectively, and diabetic rats administered 200 mg/kg metformin. The animals were sacrificed on the 22nd day of the study, the liver was excised, and different biochemical parameters were evaluated. At the end of this study, diabetic rats administered LDOGFL and HDOGFL presented significant ( p < 0.05) decreases in fragmented DNA, protein carbonyl and lipid peroxidation levels, as well as glucose-6-phosphatase, and fructose 1,6 bisphosphatase activities. However, there was a significant ( p < 0.05) increase in the levels of antioxidant biomarkers; phosphatase and transaminase activities; GLUT 2 and glycogen levels; glycogen synthase and phosphorylase; hexokinase, pyruvate kinase and glucose-6-phosphate dehydrogenase activities; and serum albumin and insulin in diabetic rats treated with extracts. Furthermore, there was a substantial increase in the relative gene expression of Nrf2 and HO-1, especially in diabetic rats administered LDOGFL. Hence, these findings suggest that these extracts might be helpful in managing hepatopathy in patients with diabetes mellitus.